Perhaps we'll find out this month - with the full HSV2 results to be released at any time in April.
Of course the thing to remember here is that we're not just seeing how good this actual vaccine is, but much more importantly! how good is the patented DNA platform technology behind it! (which can then be used by AHZ / AHZ collaborations to have a go at other diseases and cancers).
The eventual value to the SP isn't so much a single HSV2 revenue stream but HSV2 x the number of other successful vaccines.
The bluest of blue skies.
Perhaps we'll find out this month - with the full HSV2 results...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.00 |
Change
0.000(0.00%) |
Mkt cap ! $253.6M | |||
| Open | High | Low | Value | Volume |
| $11.88 | $12.00 | $11.50 | $261.8K | 22.14K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 156 | $11.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.00 | 6045 | 3 |
View Market Depth
| Last trade - 16.10pm 09/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |